Physician profile
John D Knapp
NPI 1669471207
$12,411.94
in general payments reported to CMS, 2019-2025
52 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $1,436 · 2021: $1,740 · 2022: $2,072 · 2023: $2,050 · 2024: $1,561 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,395.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,891.28 | 2019-2025 | |
| Pfizer INC. | $950.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $948.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $930.34 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Lilly USA, LLC | $916.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $913.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $699.98 | 2019-2025 | Trintellix |
| Amgen INC. | $492.30 | 2019-2024 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $426.75 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $373.75 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $364.32 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Astellas Pharma US INC | $286.18 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $267.40 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Allergan, INC. | $220.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $194.51 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.